Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | DBH | P09172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301928 | 0.85 | CNR2 (0.40) | CNR2MMP8CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL5381952 | 0.75 | MMP8 (0.47) | MMP8ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2304083 | 0.74 | CNR2 (0.36) | CNR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3798352 | 0.74 | KMT2A (0.50) | MMP8ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13547868 | 0.73 | DBH (0.41) | CACNA1HDBH | |
| SCHEMBL5198639 | 0.73 | RIPK1 (0.45) | RIPK1 | |
| SCHEMBL12802501 | 0.72 | PPARA (0.53) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3802206 | 0.72 | MMP8 (0.43) | MMP8ALDH1A1KDM4ERECQL | |
| SCHEMBL358270 | 0.71 | HSD17B2 (0.54) | ALDH1A1KDM4E | |
| SCHEMBL1492859 | 0.71 | MMP8 (0.65) | MMP8ALDH1A1RIPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2350016-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CNR2 165/4885MMP8 4591/4885CYP4F2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.